This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXMPEB280W7_M.jpg
© Reuters. RayzeBio (RYZB) IPO Opens 39% Higher
RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, opening for trading at $25 after pricing at $18 per share.
